Gastrointestinal oncology
Isofol Medical AB (publ) focuses on metastatic colorectal cancer, with clinical research centered on first-line treatment settings and anti-tumor activity in advanced disease.
- Colorectal cancer
- Metastatic disease
- First-line therapy
Its research activity reflects interest in treatment options built around fluoropyrimidine-based regimens and combination approaches used in advanced gastrointestinal malignancies.
Chemotherapy combination regimens
The sponsor investigates combination treatment strategies involving 5-fluorouracil and oxaliplatin, with added interest in regimens that incorporate bevacizumab for patients with metastatic colorectal cancer.
- 5-fluorouracil-based treatment
- Oxaliplatin-containing regimens
- Bevacizumab combinations
The clinical focus is on refining systemic therapy options within established chemotherapy backbones used in oncology.
Folate-pathway targeted therapy
Isofol Medical AB (publ) has a distinct interest in arfolitixorin, a folate-pathway agent studied as part of 5-FU-based regimens for advanced colorectal malignancy.
- Arfolitixorin
- Folate metabolism
- Combination with standard chemotherapy
This research area connects metabolic modulation with established antineoplastic treatment strategies in colorectal cancer.
Oncology safety and tolerability
The sponsor’s clinical work includes evaluation of safety and tolerability in patients with metastatic colorectal cancer, with attention to how treatment combinations are borne in routine cancer care.
- Treatment safety
- Tolerability assessment
- Advanced cancer management
Its research emphasis remains within medical oncology, particularly the clinical use of multi-agent regimens for solid tumors.
